



ASX ANNOUNCEMENT

Tax Incentive Rebate Received

Perth, Australia; 25 September 2020. NeuroScientific Biopharmaceuticals Ltd ASX: NSB ("NeuroScientific" or "the Company") is pleased to advise that the Company has received an R&D Tax Incentive rebate of approximately \$375,000 for the 2018/2019 financial year.

Following the receipt of this rebate, The Company now has capital reserves of approximately \$3.3 million.

The R&D Tax Incentive is an Australian Government program under which companies receive cash refunds for 43.5% of eligible expenditure on research and development.

About Neuroscientific Biopharmaceuticals Limited

NeuroScientific Biopharmaceuticals (ASX:NSB) is a company developing peptide-based pharmaceutical drugs that target a number of neurodegenerative conditions with high unmet medical demand. The company's product portfolio includes EmtinB, a therapeutic peptide initially targeting Alzheimer's disease and glaucoma, as well as other Emtin peptides (EmtinAc, EmtinAn, and EmtinBn) which have demonstrated similar therapeutic potential as EmtinB. For more information, please visit www.neuroscientific.com

END

Announcement authorised by the Board of Directors of NeuroScientific Biopharmaceuticals

Contacts

Matthew Liddelow
CEO and Managing Director
ml@neuroscientific.com
+61 8 6382 1805

Brian Leedman
Non-executive Chairman
bl@neuroscientific.com
+61 412 281 780